泰欣生联合放疗治疗晚期鼻咽癌的临床观察  

Clinical effect of nimotuzumab combined with radiotherapy in the treatment of advanced nasopharyngeal carcinoma

作　　者：张星霖[1] 楚蔚琳[1] 宫帅[1] 贾伟丽[1] 

机构地区：[1]青岛市立医院肿瘤科,山东青岛266011

出　　处：《现代肿瘤医学》2013年第1期55-57,共3页Journal of Modern Oncology

摘　　要：目的:评价泰欣生联合放疗治疗晚期鼻咽癌的近期疗效及不良反应。方法:符合入组标准的晚期鼻咽癌患者随机分为单纯放疗组和联合治疗组各30例,两组患者均接受根治性放射治疗,总剂量70Gy。联合治疗组同时给予泰欣生治疗,剂量为100mg/次,静脉滴注,每周给药1次。治疗结束后1月观察两组疗效及不良反应。结果:联合治疗组的完全缓解率及有效率均明显高于单纯放疗组,差异有显著性(P<0.05)。两组不良反应相似。结论:泰欣生联合放疗治疗晚期鼻咽癌的近期疗效好,与单纯放疗组比较并未增加不良反应,临床耐受性好。Objective：To evaluate the clinical effect and adverse reaction of nimotuzumab combined with radio- therapy in the treatment of advanced nasopharyngeal carcinoma. Methods： A total of 30 advanced nasopharyngeal car- cinoma patients received nimotuzumab combined with radiotherapy（ combined therapy group）, and another 30 patients received radiotherapy only（ radiotherapy group）. All patients in both groups received radical radiotherapy to the total dose of DT 70Gy. For the combining group, nimotuzumab was added at a dose of 100mg iv weekly. The clinical effect and adverse reaction was evaluated at the end of the treatment. Results： The response rate of the combining group was significantly higher than that of the radiotherapy group （ P 〈 0.05 ）. The adeverse reaction in both groups was similar. Conclusion： Nimotuzumab combined with radiotherapy in the treatment of advanced nasopharyngeal carcinoma can a- chieve a better short - term effect without cumulation of toxicity and was well - tolerated.

关 键 词：泰欣生 晚期鼻咽癌 放射治疗 

分 类 号：R739.6[医药卫生—肿瘤]